Vivos Therapeutics Inc Forecast, price target & analysts
$2.15
7.14%
yesterday
Nasdaq,
May 20, 10:00 pm CET
Vivos Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Powered by
Vivos Therapeutics Inc Classifications & Recommendation:
Buy
50%
Hold
50%
Vivos Therapeutics Inc Price Target
| Target Price | $4.23 |
| Price | $2.15 |
| Potential |
96.97%
register free of charge
|
| Number of Estimates | 2 |
|
2 Analysts have issued a price target Vivos Therapeutics Inc 2026 .
The average Vivos Therapeutics Inc target price is $4.23.
This is
96.97%
register free of charge
$6.20
189.04%
register free of charge
$2.25
4.90%
register free of charge
|
|
| A rating was issued by 2 analysts: 1 Analysts recommend Vivos Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Vivos Therapeutics Inc stock has an average upside potential 2026 of
96.97%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
Create a premium account to unlock analyst estimates.
Learn more
Powered by
Quarter
Annually
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 15.03 | 15.30 |
| 8.91% | 1.80% | |
| EBITDA Margin | -70.46% | -59.48% |
| 41.71% | 15.58% |
2 Analysts have issued a sales forecast Vivos Therapeutics Inc 2025 . The average Vivos Therapeutics Inc sales estimate is
$15.3m
Unlock
4.58%
higher
Unlock
$16.6m
13.47%
Unlock
$14.0m
4.30%
Unlock
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Vivos Therapeutics Inc 2025 . The average Vivos Therapeutics Inc EBITDA estimate is
$-9.1m
Unlock
14.87%
higher
Unlock
$-9.1m
14.87%
Unlock
$-9.1m
14.87%
Unlock
This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
Create a premium account to unlock analyst estimates.
Learn more
Powered by
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| EV/Sales | 0.76 |
Current Vivos Therapeutics Inc Upgrades & Downgrades
Create a Premium account to unlock Upgrades/Downgrades.
Learn more
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Apr 15 2025 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Nov 20 2024 |
| Alliance Global Partners |
Locked
➜
Locked
|
Locked | Nov 19 2024 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Aug 20 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Apr 15 2025 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Nov 20 2024 |
|
Locked
Alliance Global Partners:
Locked
➜
Locked
|
Nov 19 2024 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Aug 20 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
